Trial Profile
Short-Term Application of Tocilizumab Following Myocardial Infarction
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms STAT-MI
- 22 Oct 2017 Status changed from recruiting to completed.
- 29 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
- 29 Aug 2016 Planned primary completion date changed from 1 May 2017 to 1 Jun 2017.